CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 157 enrolled
Drug / intervention
Olodaterol (BI 1744) +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01040793
NCT01040793Phase 3Completed
CompareCT.gov

Randomised, Double-blind, Placebo-controlled, 3-way Cross-over Study to Determine the Effect of Treatment of Orally Inhaled BI 1744 CL (5 µg [2 Actuations of 2.5 µg] and 10 µg [2 Actuations of 5 µg]) Delivered by the Respimat® Inhaler on Exercise Endurance Time During Constant Work Rate Cycle Ergometry in Patients With Chronic Obstructive Pulmonary Disease.

Boehringer Ingelheim·interventional·Posted Dec 30, 2009·Updated Jul 8, 2014

In Brief

A Phase 3 clinical trial evaluating Olodaterol (BI 1744), Placebo, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 157 participants across 19 sites in 5 countries.

Detailed Summary

To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesAustria, Belgium, Canada, Germany, Russia
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 30, 2009
Enrollment StartJan 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.5 years ago

Interventions

Olodaterol (BI 1744)drug

Comparison of low and high dose on exercise endurance time in COPD patients

Olodaterol (BI 1744)drug

Comparison of low and high dose on exercise endurance time in COPD patients

Placebodrug

Comparison of low and high dose and placebo on exercise endurance time in COPD patients

Olodaterol (BI1744)drug

Comparison of low and high dose on exercise endurance time in COPD patients

Olodaterol (BI 1744) placebodrug

Placebo that represents olodaterol